BridgeBio's BBP-418 Hits All Endpoints in Phase 3, Normalizes Cardiac Marker in LGMD2I/R9
BBIO sits 31% above its 52-week low of $51.85.
Summary
BridgeBio's BBP-418 met all primary and secondary endpoints in the 12-month interim analysis of the Phase 3 FORTIFY trial for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Notably, 100% of treated patients normalized high-sensitivity troponin I, a cardiac damage marker, to unaffected levels by month 12, suggesting disease-modifying potential. The drug is under FDA priority review with a PDUFA date of November 27, 2026. This is the first disclosure of these pivotal efficacy results and the specific PDUFA date, representing a major de-risking event for a key pipeline asset. The data support a potential first-in-class therapy for a rare, progressive disease with no approved treatments. Investors will focus on the FDA's decision in late November and any additional long-term safety data.
At the time of this announcement, BBIO was trading at $67.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $51.85 to $93.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.